NFS1 and colorectal carcinoma: To validate the clinical correlation between NFS1 expression and the response of patients with CRC to oxaliplatin-based chemotherapy (FOLFOX or XELOX regimens), we found that NFS1 staining was increased in patients who exhibit a poorer benefit from standard chemotherapy (Fig. 7k).